CN102083499B - Ii型抗cd20抗体与蛋白酶体抑制剂的联合疗法 - Google Patents
Ii型抗cd20抗体与蛋白酶体抑制剂的联合疗法 Download PDFInfo
- Publication number
- CN102083499B CN102083499B CN200880112823.6A CN200880112823A CN102083499B CN 102083499 B CN102083499 B CN 102083499B CN 200880112823 A CN200880112823 A CN 200880112823A CN 102083499 B CN102083499 B CN 102083499B
- Authority
- CN
- China
- Prior art keywords
- ser
- antibody
- gly
- antibodies
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 243
- 108090001123 antibodies Proteins 0.000 title claims abstract description 243
- 239000003207 proteasome inhibitor Substances 0.000 title claims abstract description 61
- 238000002560 therapeutic procedure Methods 0.000 title description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 81
- 102100000165 MS4A1 Human genes 0.000 claims abstract description 79
- 101710010909 MS4A1 Proteins 0.000 claims abstract description 79
- 239000003814 drug Substances 0.000 claims abstract description 40
- 230000001225 therapeutic Effects 0.000 claims abstract description 22
- 210000004027 cells Anatomy 0.000 claims description 106
- 230000000694 effects Effects 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 21
- 229960001467 bortezomib Drugs 0.000 claims description 21
- 150000002482 oligosaccharides Polymers 0.000 claims description 18
- 229920001542 oligosaccharide Polymers 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 8
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 7
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 3
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 3
- 230000000973 chemotherapeutic Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000033581 fucosylation Effects 0.000 claims 2
- 230000001568 sexual Effects 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 38
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 36
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 34
- LDEBVRIURYMKQS-UHFFFAOYSA-N Serinyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CO LDEBVRIURYMKQS-UHFFFAOYSA-N 0.000 description 34
- 108010047857 aspartylglycine Proteins 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 31
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 28
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 27
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 27
- 108010064235 lysylglycine Proteins 0.000 description 27
- 108010078144 glutaminyl-glycine Proteins 0.000 description 26
- 108010073969 valyllysine Proteins 0.000 description 26
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 25
- 108010001645 Rituximab Proteins 0.000 description 25
- 229960004641 rituximab Drugs 0.000 description 24
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 21
- 206010025323 Lymphomas Diseases 0.000 description 21
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 21
- 239000000427 antigen Substances 0.000 description 21
- 108091007172 antigens Proteins 0.000 description 21
- 102000038129 antigens Human genes 0.000 description 21
- 108010029020 prolylglycine Proteins 0.000 description 21
- -1 such as Proteins 0.000 description 20
- 206010025310 Other lymphomas Diseases 0.000 description 19
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 19
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 19
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 19
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 108010051242 phenylalanylserine Proteins 0.000 description 19
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 18
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 18
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 18
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 18
- DRCKHKZYDLJYFQ-UHFFFAOYSA-N Isoleucyl-Threonine Chemical compound CCC(C)C(N)C(=O)NC(C(C)O)C(O)=O DRCKHKZYDLJYFQ-UHFFFAOYSA-N 0.000 description 18
- ZSXJENBJGRHKIG-UHFFFAOYSA-N Tyrosyl-Serine Chemical compound OCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UHFFFAOYSA-N 0.000 description 18
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 18
- VEYJKJORLPYVLO-RYUDHWBXSA-N Val-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VEYJKJORLPYVLO-RYUDHWBXSA-N 0.000 description 18
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 18
- 108010092854 aspartyllysine Proteins 0.000 description 18
- 108010015792 glycyllysine Proteins 0.000 description 18
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 18
- 108010080629 tryptophan-leucine Proteins 0.000 description 18
- 108010038745 tryptophylglycine Proteins 0.000 description 18
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 17
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 17
- JSLGXODUIAFWCF-UHFFFAOYSA-N Arginyl-Asparagine Chemical compound NC(N)=NCCCC(N)C(=O)NC(CC(N)=O)C(O)=O JSLGXODUIAFWCF-UHFFFAOYSA-N 0.000 description 17
- NTQDELBZOMWXRS-UHFFFAOYSA-N Aspartyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(O)=O NTQDELBZOMWXRS-UHFFFAOYSA-N 0.000 description 17
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 17
- ARPVSMCNIDAQBO-UHFFFAOYSA-N Glutaminyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CCC(N)=O ARPVSMCNIDAQBO-UHFFFAOYSA-N 0.000 description 17
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 17
- WMDZARSFSMZOQO-DRZSPHRISA-N Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WMDZARSFSMZOQO-DRZSPHRISA-N 0.000 description 17
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 17
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 17
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 17
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 17
- GJNDXQBALKCYSZ-RYUDHWBXSA-N Val-Phe Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 GJNDXQBALKCYSZ-RYUDHWBXSA-N 0.000 description 17
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 17
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 17
- 108010008355 arginyl-glutamine Proteins 0.000 description 17
- 230000003899 glycosylation Effects 0.000 description 17
- 238000006206 glycosylation reaction Methods 0.000 description 17
- 108010056582 methionylglutamic acid Proteins 0.000 description 17
- 108010009962 valyltyrosine Proteins 0.000 description 17
- BVZABQIRMYTKCF-JSGCOSHPSA-N (2S)-2-[[(2S)-2-azaniumyl-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(O)=O)=CNC2=C1 BVZABQIRMYTKCF-JSGCOSHPSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- RGGVDKVXLBOLNS-UHFFFAOYSA-N Asparaginyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CC(N)=O)N)C(O)=O)=CNC2=C1 RGGVDKVXLBOLNS-UHFFFAOYSA-N 0.000 description 15
- 210000004369 Blood Anatomy 0.000 description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 15
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 15
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 108010045030 monoclonal antibodies Proteins 0.000 description 15
- 102000005614 monoclonal antibodies Human genes 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- NGWSFRIPKNWYAO-SHTIJGAHSA-N Salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 14
- 229940088598 Enzyme Drugs 0.000 description 13
- 201000009030 carcinoma Diseases 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 108010079364 N-glycylalanine Proteins 0.000 description 12
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 11
- HAYVTMHUNMMXCV-UHFFFAOYSA-N Cysteinyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CS HAYVTMHUNMMXCV-UHFFFAOYSA-N 0.000 description 11
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 11
- 241001597008 Nomeidae Species 0.000 description 11
- 108091006028 chimera Proteins 0.000 description 11
- 108010044655 lysylproline Proteins 0.000 description 11
- 230000003442 weekly Effects 0.000 description 11
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 10
- MRVYVEQPNDSWLH-UHFFFAOYSA-N Glutaminyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)CCC(N)=O MRVYVEQPNDSWLH-UHFFFAOYSA-N 0.000 description 9
- 241000880493 Leptailurus serval Species 0.000 description 9
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 9
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 9
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 8
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 8
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 8
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 8
- FFOKMZOAVHEWET-UHFFFAOYSA-N Serinyl-Cysteine Chemical compound OCC(N)C(=O)NC(CS)C(O)=O FFOKMZOAVHEWET-UHFFFAOYSA-N 0.000 description 8
- XXDVDTMEVBYRPK-XPUUQOCRSA-N Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O XXDVDTMEVBYRPK-XPUUQOCRSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000000295 complement Effects 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N epoxyketone group Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- SITLTJHOQZFJGG-XPUUQOCRSA-N α-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 description 8
- XPJBQTCXPJNIFE-ZETCQYMHSA-N (2S)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]-4-methylpentanoate Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 7
- 108010049171 IPSI-001 Proteins 0.000 description 7
- 102000018358 Immunoglobulins Human genes 0.000 description 7
- 108060003951 Immunoglobulins Proteins 0.000 description 7
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 7
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002797 proteolythic Effects 0.000 description 7
- 210000004881 tumor cells Anatomy 0.000 description 7
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229960003171 Plicamycin Drugs 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 108010017796 epoxidase Proteins 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 201000009251 multiple myeloma Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 5
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 5
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 5
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 5
- 229960004397 Cyclophosphamide Drugs 0.000 description 5
- 229960000975 Daunorubicin Drugs 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 5
- 206010024324 Leukaemias Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- NLKUJNGEGZDXGO-XVKPBYJWSA-N Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLKUJNGEGZDXGO-XVKPBYJWSA-N 0.000 description 5
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 108010021331 carfilzomib Proteins 0.000 description 5
- 229960002438 carfilzomib Drugs 0.000 description 5
- 239000006143 cell culture media Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000003203 everyday Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- 229960004117 Capecitabine Drugs 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 229960004630 Chlorambucil Drugs 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 229960000640 Dactinomycin Drugs 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 229960004679 Doxorubicin Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 206010017758 Gastric cancer Diseases 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 210000004408 Hybridomas Anatomy 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 210000004698 Lymphocytes Anatomy 0.000 description 4
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 4
- 229960004961 Mechlorethamine Drugs 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 210000001672 Ovary Anatomy 0.000 description 4
- 230000035980 PAA Effects 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 102000035443 Peptidases Human genes 0.000 description 4
- 108091005771 Peptidases Proteins 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 4
- 229960001052 Streptozocin Drugs 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000000259 anti-tumor Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 108010037850 glycylvaline Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000006439 lymphocytic leukemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 239000010413 mother solution Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 229920001888 polyacrylic acid Polymers 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 3
- BLMFNYXTSPNJSB-UHFFFAOYSA-N 1-chloro-4-[2-[3-(4-chlorophenyl)prop-1-en-2-ylsulfonyl]prop-2-enyl]benzene Chemical compound C1=CC(Cl)=CC=C1CC(=C)S(=O)(=O)C(=C)CC1=CC=C(Cl)C=C1 BLMFNYXTSPNJSB-UHFFFAOYSA-N 0.000 description 3
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- PGGUOGKHUUUWAF-ROUUACIJSA-N Calpeptin Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 PGGUOGKHUUUWAF-ROUUACIJSA-N 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N Epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 description 3
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- DAQAKHDKYAWHCG-RWTHQLGUSA-N Lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 3
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229960005454 Thioguanine Drugs 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102400000757 Ubiquitin Human genes 0.000 description 3
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229930013930 alkaloids Natural products 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- VPZXBVLAVMBEQI-VKHMYHEASA-N gly ala Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010010147 glycylglutamine Proteins 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 238000005497 microtitration Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000006845 reticulosarcoma Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
- FWPWHHUJACGNMZ-NBBQQVJHSA-N (1S,2R,5R)-5-[(1S)-1-hydroxy-2-methylpropyl]-2-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione Chemical compound N1C(=O)[C@H](C)[C@@H]2OC(=O)[C@@]21[C@@H](O)C(C)C FWPWHHUJACGNMZ-NBBQQVJHSA-N 0.000 description 2
- UCXQIIIFOOGYEM-ULQDDVLXSA-N (2S)-2-[[(2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 2
- RSYTXXARKSZDKY-CGZPKHFZSA-N (2S)-2-[[2-(4-hydroxy-3-iodo-5-nitrophenyl)acetyl]amino]-4-methyl-N-[(2S)-4-methyl-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopentan-2-yl]pentanamide Chemical compound CS(=O)(=O)/C=C/[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CC1=CC(I)=C(O)C([N+]([O-])=O)=C1 RSYTXXARKSZDKY-CGZPKHFZSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 229960003272 ASPARAGINASE Drugs 0.000 description 2
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 210000002940 B-Lymphoid Precursor Cells Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
- 229960001950 Benzethonium Chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108050006400 Cyclins Proteins 0.000 description 2
- 102000016736 Cyclins Human genes 0.000 description 2
- RGTVXXNMOGHRAY-UHFFFAOYSA-N Cysteinyl-Arginine Chemical compound SCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RGTVXXNMOGHRAY-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229960003957 Dexamethasone Drugs 0.000 description 2
- 101700057458 Drice Proteins 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940020967 Gemzar Drugs 0.000 description 2
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 2
- 229960000908 Idarubicin Drugs 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 229960001101 Ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- 102000003996 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon beta Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 229960001388 Interferon-beta Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- UWBDLNOCIDGPQE-UHFFFAOYSA-N Isoleucyl-Lysine Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)CCCCN UWBDLNOCIDGPQE-UHFFFAOYSA-N 0.000 description 2
- 210000000244 Kidney Pelvis Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-M L-glutaminate Chemical compound [O-]C(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-M 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 description 2
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 2
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 description 2
- 206010061232 Lymphoproliferative disease Diseases 0.000 description 2
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027191 Meningioma Diseases 0.000 description 2
- 229960004635 Mesna Drugs 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- IUDBVFIQSSOIDB-TWOQFEAHSA-N N-[(2S)-3-hydroxy-1-[[(2S)-1-[(2R)-2-(hydroxymethyl)oxiran-2-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-methylheptanamide Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(CO)CO1 IUDBVFIQSSOIDB-TWOQFEAHSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 210000004011 Plasma Cells Anatomy 0.000 description 2
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 229940063179 Platinol Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- SHAQGFGGJSLLHE-BQBZGAKWSA-N Pro-Gln Chemical compound NC(=O)CC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 SHAQGFGGJSLLHE-BQBZGAKWSA-N 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010038038 Rectal cancer Diseases 0.000 description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229940063683 Taxotere Drugs 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 2
- YKRQRPFODDJQTC-UHFFFAOYSA-N Threoninyl-Lysine Chemical compound CC(O)C(N)C(=O)NC(C(O)=O)CCCCN YKRQRPFODDJQTC-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 229950001353 Tretamine Drugs 0.000 description 2
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 2
- UBAQSAUDKMIEQZ-QWRGUYRKSA-N Tyr-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UBAQSAUDKMIEQZ-QWRGUYRKSA-N 0.000 description 2
- MFEVVAXTBZELLL-UHFFFAOYSA-N Tyrosyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- 210000000626 Ureter Anatomy 0.000 description 2
- 206010046766 Uterine cancer Diseases 0.000 description 2
- 210000004291 Uterus Anatomy 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 229940053867 Xeloda Drugs 0.000 description 2
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 101710014494 celI Proteins 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229960001411 chlormethine Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 201000010915 glioblastoma multiforme Diseases 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine zwitterion Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007919 intrasynovial administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 2
- 229960001786 megestrol Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 125000000405 phenylalanyl group Chemical group 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- 201000005746 pituitary adenoma Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- DXJZITDUDUPINW-UHFFFAOYSA-N γ-glutamyl-Asparagine Chemical compound NC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O DXJZITDUDUPINW-UHFFFAOYSA-N 0.000 description 2
- LQJAALCCPOTJGB-YUMQZZPRSA-N (2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- DEISXDMEXOTAHD-FKLPMGAJSA-N (2S)-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-phenylpropanoic acid;1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C.N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)OCC1=CC=CC=C1 DEISXDMEXOTAHD-FKLPMGAJSA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1H-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
- ALZVPLKYDKJKQU-XVKPBYJWSA-N Ala-Tyr Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ALZVPLKYDKJKQU-XVKPBYJWSA-N 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
- HXWUJJADFMXNKA-UHFFFAOYSA-N Asparaginyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC(N)=O HXWUJJADFMXNKA-UHFFFAOYSA-N 0.000 description 1
- VBKIFHUVGLOJKT-UHFFFAOYSA-N Asparaginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(N)=O VBKIFHUVGLOJKT-UHFFFAOYSA-N 0.000 description 1
- BSWHERGFUNMWGS-UHFFFAOYSA-N Aspartyl-Isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(O)=O BSWHERGFUNMWGS-UHFFFAOYSA-N 0.000 description 1
- 206010073480 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- WXOFKRKAHJQKLT-UHFFFAOYSA-N Cysteinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CS WXOFKRKAHJQKLT-UHFFFAOYSA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940026692 Decadron Drugs 0.000 description 1
- 229960004833 Dexamethasone phosphate Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- 206010013683 Drug effect increased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 229940098617 Ethyol Drugs 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101700076345 GSTA1 Proteins 0.000 description 1
- 101700078985 GSTA2 Proteins 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- CLSDNFWKGFJIBZ-UHFFFAOYSA-N Glutaminyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CCC(N)=O CLSDNFWKGFJIBZ-UHFFFAOYSA-N 0.000 description 1
- HHSJMSCOLJVTCX-UHFFFAOYSA-N Glutaminyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCC(N)=O HHSJMSCOLJVTCX-UHFFFAOYSA-N 0.000 description 1
- KGVHCTWYMPWEGN-FSPLSTOPSA-N Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-FSPLSTOPSA-N 0.000 description 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 description 1
- UCGDDTHMMVWVMV-FSPLSTOPSA-N Ile-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(O)=O UCGDDTHMMVWVMV-FSPLSTOPSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229940055742 Indium-111 Drugs 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N L-tyrosyl-L-tyrosine Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- JYOAXOMPIXKMKK-UHFFFAOYSA-N Leucyl-Glutamine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CCC(N)=O JYOAXOMPIXKMKK-UHFFFAOYSA-N 0.000 description 1
- 208000001152 Leukemia, Prolymphocytic, B-Cell Diseases 0.000 description 1
- 229940063725 Leukeran Drugs 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 208000002502 Lymphedema Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 208000009285 Lymphoma, Large B-Cell, Diffuse Diseases 0.000 description 1
- FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- MUMXFARPYQTTSL-BQBZGAKWSA-N Met-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O MUMXFARPYQTTSL-BQBZGAKWSA-N 0.000 description 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229940090009 Myleran Drugs 0.000 description 1
- 210000004693 NK cell Anatomy 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 240000004678 Panax pseudoginseng Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 210000002990 Parathyroid Glands Anatomy 0.000 description 1
- 210000003899 Penis Anatomy 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- WEQJQNWXCSUVMA-RYUDHWBXSA-N Phe-Pro Chemical compound C([C@H]([NH3+])C(=O)N1[C@@H](CCC1)C([O-])=O)C1=CC=CC=C1 WEQJQNWXCSUVMA-RYUDHWBXSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 1
- 208000006781 Prolymphocytic Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100007381 SORT1 Human genes 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- RZEQTVHJZCIUBT-UHFFFAOYSA-N Serinyl-Arginine Chemical compound OCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-UHFFFAOYSA-N 0.000 description 1
- LZLREEUGSYITMX-UHFFFAOYSA-N Serinyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 1
- ONWMQORSVZYVNH-UHFFFAOYSA-N Tyrosyl-Asparagine Chemical compound NC(=O)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 ONWMQORSVZYVNH-UHFFFAOYSA-N 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- LXQXZNRPTYVCNG-YPZZEJLDSA-N americium-241 Chemical compound [241Am] LXQXZNRPTYVCNG-YPZZEJLDSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001905 anti-neuroblastoma Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 102000026868 carbohydrate binding proteins Human genes 0.000 description 1
- 108091007726 carbohydrate binding proteins Proteins 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- GUTLYIVDDKVIGB-YPZZEJLDSA-N cobalt-57 Chemical compound [57Co] GUTLYIVDDKVIGB-YPZZEJLDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000005035 ginseng Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N gly-val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000000749 insecticidal Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 201000003913 parathyroid carcinoma Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000001586 pre-B-lymphocyte Anatomy 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 210000001948 pro-B lymphocyte Anatomy 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 108010014657 sortilin Proteins 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- GYLUMIIRFKDCKI-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dihydroxide Chemical compound [OH-].[OH-].C[N+](C)(C)CCCCCC[N+](C)(C)C GYLUMIIRFKDCKI-UHFFFAOYSA-L 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UKKNTTCNGZLJEX-UHFFFAOYSA-N γ-glutamyl-Serine Chemical compound NC(=O)CCC(N)C(=O)NC(CO)C(O)=O UKKNTTCNGZLJEX-UHFFFAOYSA-N 0.000 description 1
Abstract
本发明涉及II型抗CD20抗体在制备用于与蛋白酶体抑制剂联合治疗癌症,尤其是表达CD20的癌症的药物中的应用。
Description
本发明涉及II型抗CD20抗体在制备用于与蛋白酶体抑制剂联合治疗癌症,尤其是表达CD20的癌症的药物中的应用。
发明背景
CD20分子(也称为人B淋巴细胞限制性分化抗原或Bp35)是一种位于前B(pre-B)和成熟B淋巴细胞上的分子量约35kD的疏水跨膜蛋白(Valentine,等人,J.Biol.Chem.(生物化学杂志)264(19)(1989)11282-11287;和Einfield,D.A.等人,EMBO J.(EMBO杂志)7(3)(1988)711-717)。CD20见于90%以上的来自外周血或淋巴样器官的B细胞的表面上,其在早期前B细胞发育期间表达并且一直存在直至浆细胞分化。CD20存在于正常B细胞以及恶性B细胞上。具体地,CD20在90%以上的B细胞非霍奇金淋巴瘤(NHL)上表达(Anderson,K.C.等人,Blood(血液)63(6)(1984)1424-1433),但不存在于造血干细胞、原B细胞(pro-Bcells)、正常浆细胞或其他正常组织中(Tedder,T.F.等人,J,Immunol.(免疫学杂志)135(2)(1985)973-979)。
CD20蛋白的85个氨基酸羧基末端区位于胞质中。此区的长度与其他B细胞特异的表面结构相反,上述表面结构诸如IgM、IgD和IgG重链或组织相容性抗原I1类α或β链,它们具有相对短的胞质内区域,分别具有3、3、28、15和16个氨基酸(Komaromy,M.等人,NAR(核酸研究)11(1983)6775-6785)。在最后61个羧基末端氨基酸中,21个是酸性残基,而仅有2个是碱性残基,表明该区具有很强的净负电荷。GenBank登记号为NP-690605。CD20被认为可能参与调节B细胞活化和分化过程中的(多个)早期步骤(Tedder,T.F.等人,Eur.J.Immunol.(欧洲免疫学杂志)16第8期(1986)881-887)并且可具有钙离子通道的功能(Tedder,T.F.等人,J.Cell.Biochem.(细胞生物化学杂志)14D(1990)195)。
存在有两种不同类型的抗CD20抗体,两者在其CD20结合模式和生物学活性方面明显不同(Cragg,M.S.等人,Blood(血液)103(2004)2738-2743;和Cragg,M.S.等人,Blood(血液)101(2003)1045-1052)。I型抗体,例如,利妥昔单抗(rituximab),在补体介导的细胞毒性中发挥作用,而II型抗体,例如,托西莫单抗(Tositumomab)(B1)、11B8、AT80或人源化B-Ly1抗体,能有效地经胱天蛋白酶(caspase)非依赖性凋亡启动靶细胞死亡并伴随着磷脂酰丝氨酸的暴露。
I型和II型抗CD20抗体共有的通用特性总结在表1中。
表1:
I型和II型抗CD20抗体的特性
I型抗CD20抗体 | II型抗CD20抗体 |
I型CD20表位 | II型CD20表位 |
将CD20定位在脂膜筏 | 不将CD20定位在脂膜筏 |
增加的CDC(如果为IgG1同种型) | 减少的CDC(如果为IgG1同种型) |
ADCC活性(如果为IgG1同种型) | ADCC活性(如果为IgG1同种型) |
完全结合力 | 减少的结合力 |
同型聚集 | 较强的同型聚集 |
在交联时诱导凋亡 | 在不交联条件下的强细胞死亡诱导作用 |
26S蛋白酶体,也称为多催化活性蛋白酶复合体(multicatalyticproteinasecomplex),其是在大量真核细胞类型的胞质和核中发现的一种极高分子量复合体(26S)。蛋白酶体由20S中央催化核心和两个19S调节帽组成。19S调节帽见于20S桶状复合体的各端处并调节底物进入中央催化核心中。19S帽在底物的识别中具有重要作用,该底物已经通过添加多个8.5kDa多肽遍在蛋白分子而成为降解的靶标(其综述,例如,见Coux,O.,Tanaka,K.和Goldberg,A.,Ann.Rev.Biochem.(生物化学年鉴)65(1996)801-847;Voges,D.,Annu RevBiochem.(生物化学年鉴)68(1999)1015-68和Kisselev,A.L.等人,Chem Biol(化学与生物学)Vol.8(8)(2001)739-758)。在促进遍在蛋白分子从底物上去除后,当底物进入中央催化核心时19S帽促进底物蛋白去折叠。
26S蛋白酶体在进化上是高度保守的,在被研究的所有真核细胞上都已发现其存在,并且其可占组织匀浆中总蛋白的至多1.0%。在细胞的胞质和核中都已经发现有蛋白酶体,表明其在这些区室内的功能地位(Tanaka,K.等人,J.Cell Physiol.(细胞生理学杂志)139(1989)34-41;Amsterdam,A.,等人,Proc.Natl.Acad.Sci.USA(美国国家科学院院报)90(1993)99-103。
对蛋白酶体的早期研究产生了5种不同蛋白水解活性的描述,每种都与该复合体的不同组分有关(Wilk,S.,和Orlowski,M.,J Neurochem.(神经化学杂志)35(1980)1172-1182;Wilk,S.,和Orlowski,M.,J Neurochem.(神经化学杂志)40(1983)842-849;Orlowski,M.,和Wilk,S.,Biochem.Biophys.Res.Comm(生物化学与生物物理研究通讯)101(1981)814-822)。三种主要活性在特异性方面类似于糜蛋白酶、胃蛋白酶和肽谷氨酰基肽酶。描述的两种其他活性显示优先裂解支链氨基酸羧基侧上的肽键并朝向短链中性氨基酸之间的肽键裂解(Orlowski,M.,Biochemistry(生物化学)29(1990)10289-297)。
现在已明确蛋白酶体是一种主要的溶酶体外蛋白水解系统,其参与对多种不同的细胞功能很重要的蛋白水解通路,这些细胞功能诸如细胞分裂、抗原加工和短寿命调控蛋白(诸如癌蛋白、转录因子和细胞周期蛋白)的降解(Ciechanover,A.,Cell(细胞)79(1994)13-21;Palombell,V.J.,Rando,O.J.,Goldberg,A.L.和Maniatis,T.,Cell(细胞)78(1994)773-785)。由于蛋白.酶体在细胞周期的进程期间细胞周期蛋白的有序降解中具有关键的作用,因此其在细胞分裂中具有一定的作用。其他的研究证明编码酵母蛋白酶体亚单位的13条基因中12条的任意一条的破坏都将导致细胞增殖的停止或不能降解蛋白,也表明了蛋白酶体在细胞生长中的作用(Fuiiwara,T.等人,J.Biol.Chem.(生物化学杂志)265(1990)16604-1613;Beynon,Int.Committee on Proteolysis News Letter(国际蛋白水解学会动态),1月,1-2(1994))。因此蛋白酶体的抑制可能在由异常细胞分裂引起的疾病如癌症的治疗中是有用的。
观察到遍在蛋白介导的蛋白酶体蛋白水解在NFkB活化中的关键性作用,其可在临床上被利用来应用针对蛋白酶体的抑制剂。NFkB活性形式的形成需要蛋白酶体介导的p105(NFkB的无活性前体)的蛋白水解。
另外,NFkB的加工形式(p65/p50)作为与抑制性蛋白IkB结合的无活性复合体存在于胞质中。各种刺激通过启动导致蛋白酶体介导的IkB降解的信号传导通路而活化NFkB。在多种炎性疾病和感染性两类疾病中已经观察到NFkB的异常活化,紧接着刺激细胞因子合成。NFkB的活化对于血管发生和细胞粘附分子的表达也是很重要的,并且因此蛋白酶体抑制剂也可用于与血管系统相关的疾病的治疗中。
如例如,Kisselev,A.L.等人,Chem Biol(化学与生物学)Vol.8(8)(2001)739-758、WO 2004/004749和Joazeiro,C.等人,Cancer Res.(癌症研究)66(16)(2006)7840-7842中所述,已经存在有多种蛋白酶体抑制剂,它们都具有抑制26S蛋白酶体活性的相同性质。这些蛋白酶体抑制剂包括,尤其是,例如,肽衍生物诸如肽醛(peptide aldehyde)(例如,MG132)、MG115、CEP-1615或PSI),肽硼酸盐(peptide boronate)(例如,硼替佐米(PS-341)或DFLB),肽环氧酮(peptide epoxyketone)(例如,环氧酶素(epoxomicin)、dihydroeponemycin或环氧酶素衍生物(epoxomicin derivative)PR-171),或肽乙烯基砜(peptide vinyl sulfone)(例如,NLVS)以及非肽衍生物诸如salinosporamide A(NPI-0052)、salinosporamide A衍生物、乳胞素(lactacystin)或乳胞素衍生物(例如,clasto-乳胞素-L-内酯(clasto-lactacystin-L-lactone)(omuralide)或PS-519)(在Kisselev,A.L.等人,Chem Biol(化学生物学)Vol.8(8)(2001)739-758、WO 2004/004749和Joazeiro,C.等人,Cancer Res.(癌症研究)66(16)(2006)7840-7842中)。
Smolewski,P.等人,Leukemia Research(白血病研究)30(2006)1521-1529描述了硼替佐米和利妥昔单抗(一种I型抗CD20抗体)的累加的体外细胞毒效应。Wang,M.等人,Leukemia(白血病),22(2008)179-185描述了硼替佐米、利妥昔单抗和环磷酰胺三重组合的体外效应和在一个外套膜(mantle)细胞淋巴瘤异种移植物模型中的效应。
发明概述
本发明包括II型抗CD20抗体在制备用于与蛋白酶体抑制剂联合治疗表达CD20的癌症的药物中的应用。
本发明进一步包括II型抗CD20抗体在制备用于与蛋白酶体抑制剂联合治疗患有表达CD20的癌症的患者的药物中的应用。
优选地,所述蛋白酶体抑制剂的抗蛋白酶体抑制活性的IC50为5μM或更小。
优选地,所述II型抗CD20抗体具有的所述II型CD20抗体与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值为0.3~0.6,更优选为0.35~0.55,并且还更优选为0.4~0.5。
优选地,所述II型抗CD20抗体是人源化B-Ly1抗体。
优选地,所述II型抗CD20抗体具有提高的抗体依赖性细胞毒性(ADCC)。
优选地,所述蛋白酶体抑制剂选自由肽醛、肽硼酸盐、肽环氧酮或salinosporamide A组成的组。
发明详述
术语“抗体”包涵各种形式的抗体,其包括但不限于全抗体、人抗体、人源化抗体和基因工程抗体如单克隆抗体、嵌合抗体或重组抗体,以及这些抗体的片段,只要保留了根据本发明的特征性。
如在此使用的术语“单克隆抗体”或“单克隆抗体组合物”指具有单一氨基酸组成的抗体分子的制剂。因此,术语“人单克隆抗体”指显示单一结合特异性的抗体,其具有来自人胚系免疫球蛋白序列的可变区和恒定区。在一个实施方案中,人单克隆抗体由杂交瘤产生,该杂交瘤包括与永生化细胞融合的从转基因非人动物,例如,转基因小鼠获得的B细胞,其具有包括人重链转基因和轻链转基因的基因组。
优选地,所述II型抗CD20抗体是单克隆抗体。
术语“嵌合抗体”指通常通过重组DNA技术制备的包括来自一个来源或物种的可变区,即,结合区,和来自不同来源或物种的至少一部分恒定区的单克隆抗体。特别优选包括鼠可变区和人恒定区的嵌合抗体。这些鼠/人嵌合抗体是包括编码鼠免疫球蛋白可变区的DNA节段和编码人免疫球蛋白恒定区的DNA节段的免疫球蛋白基因表达的产物。本发明包涵的其他形式的“嵌合抗体”是其中原始抗体的类别或亚类已经被修饰或改变的那些抗体。此类“嵌合”抗体也称为“类别转换抗体(class-switchedantibody)”。用于产生嵌合抗体的方法涉及现在本领域公知的常规重组DNA和基因转染技术。见,例如,Morrison,S.L.等人,Proc.Natl.Acad Sci.USA(美国科学院学报)81(1984)6851-6855;US 5,202,238和US 5,204,244。
术语“人源化抗体”指其中框架或“互补决定区”(CDR)已经被修饰从而包括特异性与亲代免疫球蛋白不同的免疫球蛋白的CDR的抗体。在优选的实施方案中,鼠CDR移植至人抗体的框架区以制备“人源化抗体”,见,例如,Riechmann,L.等人,Nature(自然)332(1988)323-327;和Neuberger,M.S.等人,Nature(自然)314(1985)268-270。对于嵌合和双功能抗体,特别优选CDR对应于那些识别上述抗原的代表序列。
在此使用的术语“人抗体”意在包括具有来源于人胚系免疫球蛋白序列的可变区和恒定区的抗体。人抗体在本领域中是公知的(van Dijk,M.A.和van de Winkel,J.G.,Curr.Opin.Chem.Biol.(化学与生物学新观点)5(2001)368-374)。基于此技术,可产生针对大量靶标的人抗体。人抗体的例子,例如,描述在Kellermann,S.A.等人,Curr OpinBiotechnol.(生物技术新观点)13(2002)593-597中。
在此使用的术语“重组人抗体”意在包括通过重组方式制备、表达、构建或分离的所有人抗体,诸如从诸如NS0或CHO细胞的宿主细胞分离的抗体或从人免疫球蛋白基因转基因的动物(例如,鼠)分离的抗体或使用转染进宿主细胞的重组表达载体表达的抗体。这些重组人抗体具有重排形式的来源于人胚系免疫球蛋白序列的可变区和恒定区。根据本发明的重组人抗体已经进行了体内体细胞高度突变。因此,重组抗体的VH和VL区的氨基酸序列是,尽管来源于人胚系VH和VL序列和并与两者相关,但不可以天然地存在于体内人抗体胚系所有成分之内的序列。
在此使用的“特异性结合”或“特异性地结合于”指抗体特异性地结合于CD20抗原。优选地,结合亲和力是10-8mol/l或更低,优选地10-9mol/l或更低(例如,10-10mol/l)的KD值,更优选具有10-10mol/l或更低(例如,10-12mol/l)的KD值。结合亲和力采用标准的结合测定法诸如斯卡恰特作图分析(Scatchard plot analysis)(例如Biacore)在CD20表达细胞上测定。
在此使用的术语“核酸分子”意在包括DNA分子和RNA分子。核酸分子可以是单链或双链的,但优选是双链DNA。
“恒定区”不直接参与抗体与抗原的结合,但参与效应器功能(ADCC,补体结合以及CDC)。
在此使用的“可变区”(轻链的可变区(VL),重链的可变区(VH))是指直接参与抗体与抗原结合的一对轻链和重链中的每一个。可变的人轻链和重链的结构域具有相同的通用结构,并且各个结构域包括由三个“超变区”(或互补决定区,CDR)连接的四个框架(FR)区,框架区的序列是广泛保守的。框架区采用b-折叠构象,并且CDR可形成连接b-折叠结构的环。各个链内的CDR通过框架区保持其三维结构,并且与来自其他链的CDR一起形成抗原结合位点。抗体重链和轻链CDR3区在本发明所述的抗体的结合特异性/亲和力中具有特别重要的作用,并且因此提供了本发明的进一步的目的。
术语“超变区”或“抗体的抗原结合部分”当在此使用时指抗体负责抗原结合的氨基酸残基。超变区包括来自“互补决定区”或“CDR”的氨基酸残基。“框架区”或“FR”区是如在此所定义的超变区残基之外的那些可变区结构域。因此,抗体的轻链和重链从N末端至C末端包括结构域FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。尤其是,重链的CDR3是对抗原结合贡献最多的区。根据Kabat,E.A.等人,Sequences of Proteins ofImmunological Interest(具有免疫学重要性的蛋白序列),第五版,PublicHealth Service(公共医疗),NationalInstitutes of Health(国立卫生研究院),Bethesda,MD.(1991))的标准定义和/或来自“超变环”的那些残基来确定CDR和FR区。
术语“CD20”和“CD抗原”在此互换使用,并且包括由细胞天然表达的或用CD20基因转染的细胞上表达的人CD20的任何变异体、同种型和物种同源物。本发明的抗体与CD20抗原的结合通过使CD20失活来介导表达CD20的细胞(例如,肿瘤细胞)的杀伤。表达CD20的细胞的杀伤可通过下列机制的一种或多种来发生:细胞死亡/凋亡诱导、ADCC和/或CDC。
如本领域中公认的,CD20的同义词包括B淋巴细胞抗原CD20、B淋巴细胞表面抗原B1、Leu-16、Bp35、BM5和LF5。
根据本发明术语“抗CD20抗体”是与CD20抗原特异性结合的抗体。取决于抗CD20抗体与CD20抗原的结合特性和生物活性,根据Cragg,M.S.等人,Blood(血液)103(2004)2738-2743;和Cragg,M.S.等人,Blood(血液)101(2003)1045-1052可区分为两种类型的抗CD20抗体(I型和II型抗CD20抗体),见表2。
表2:
I型和II型抗CD20抗体的特性
I型抗CD20抗体 | II型抗CD20抗体 |
I型CD20表位 | II型CD20表位 |
将CD20定位在脂膜筏 | 不将CD20定位在脂膜筏 |
增加的CDC(如果为IgG1同种型) | 减少的CDC(如果为IgG1同种型) |
ADCC活性(如果为IgG1同种型) | ADCC活性(如果为IgG1同种型) |
完全结合力 | 较低的结合力 |
同型聚集 | 较强的同型聚集 |
在交联时诱导凋亡 | 在不交联条件下的强的细胞死亡诱导作用 |
I型和II型抗CD20抗体的一个基本特性是其结合模式。因此,I型和II型抗CD20抗体可通过所述抗CD20抗体的与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值来分类。
II型抗CD20抗体具有的所述抗CD20抗体的与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗的比值为0.3~0.6,优选0.35~0.55,更优选0.4~0.5。此类II型抗CD20抗体的例子包括,例如,托西莫单抗(B1IgG2a),人源化B-Ly1抗体IgG1(如WO 2005/044859中所公开的嵌合人源化IgG1抗体)、11B8 IgG1(如WO 2004/035607中所公开的)和AT80IgG1。优选地所述II型抗CD20抗体是与人源化B-Ly1抗体(如WO2005/044859中所公开的)结合相同的表位的单克隆抗体。
与II型抗体相反,I型抗CD20抗体具有的所述抗CD20抗体的与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗的比值为0.8~1.2,优选0.9~1.1。此类I型抗CD20抗体的例子包括例如,利妥昔单抗、1F5IgG2a(ECACC,杂交瘤;Press,O.W.等人,Blood(血液)69/2(1987)584-591)、HI47 IgG3(ECACC,杂交瘤)、2C6 IgG1(如WO 2005/103081中所公开的)、2F2 IgG1(如WO 2004/035607和WO 2005/103081中所公开的)以及2H7 IgG1(如WO 2004/056312中所公开的)。
“抗CD20抗体的与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗的比值”通过直接免疫荧光测定法(测定平均荧光强度(MFI))使用与Cy5缀合的所述抗CD20抗体和与Cy5缀合的利妥昔单抗与Raji细胞(ATCC编号:CCL-86)在FACSArray(BectonDickinson)中测定,如实施例2中所述,并且如下进行计算:
MFI是平均荧光强度。在此使用的“Cy5-标记比例”指每分子抗体的Cy5-标记分子的数目。
典型地,所述II型抗CD20抗体具有的所述二级抗CD20抗体与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值为0.3~0.6,更优选为0.35~0.55,更优选为0.4~0.5。
在优选的实施方案中,所述II型抗CD20抗体,优选人源化B-Ly1抗体具有增加的抗体依赖性细胞毒性(ADCC)。
“具有增加的抗体依赖性细胞毒性(ADCC)的抗体”是指如在此所定义的该术语一样,具有根据本领域普通技术人员已知的任何适当的方法测定的增加的ADCC的抗体。一种公认的体外ADCC测定法如下:
1)该测定法使用已知表达被抗体的抗原结合区识别的靶抗原的靶细胞;
2)该测定法使用从随机选择的健康供体的血液分离的人外周血单核细胞(PBMCs)作为效应细胞;
3)该测定法根据下列的试验方案进行:
i)PBMC使用标准的密度离心步骤分离,并以5×106细胞/ml悬浮在RPMI细胞培养基中;
ii)靶细胞通过标准的组织培养方法生长,从指数生长期收获,活力大于90%,在RPMI细胞培养基中洗涤,用100微居里51Cr标记,用细胞培养基洗涤两次,并且以105细胞/ml的密度重新悬浮在细胞培养基中;
iii)将100微升的上述最终靶细胞悬液转移至96孔微量滴定板的各孔中;
iv)抗体在细胞培养基中从4000ng/ml连续稀释至0.04ng/ml,并将50微升所得抗体溶液加入至96孔微量滴定板中的靶细胞中,将上面全部浓度范围内的各个抗体浓度检测三次;
v)对于最大释放(MR)对照,含有标记靶细胞的板中的另外3个孔加入50微升2%(VN)非离子型去污剂(Nonidet,Sigma,St.Louis)的水溶液代替抗体溶液(上面的iv点);
vi)对于自发释放(SR)对照,含有标记靶细胞的板中的另外3个孔加入50微升RPMI细胞培养基代替抗体溶液(上面iv点);
vii)然后96孔微量滴定板以50×g离心1分钟,并在4℃下孵育1小时;
viii)将50微升PBMC悬液(上面i点)加入至各孔中以产生25∶1的效应细胞∶靶细胞比例,并且将平板置于培养箱中在5%CO2气氛中37℃下4小时;
ix)从各孔收获不含细胞的上清液,并且使用γ计数器定量实验释放的放射性(ER);
x)根据式(ER-MR)/(MR-SR)×100对各抗体浓度计算特异性溶解的百分数,其中ER是对该抗体浓度定量的平均放射性(见上面的ix点),MR为对MR对照(见上面的v点)定量的平均放射性(见上面的ix点),以及SR是对SR对照(见上面的vi点)定量的平均放射性(见上面的ix点);
4)“增加的ADCC”被规定为上面检测的抗体浓度范围内观察到的特异性溶解的最大百分数,和/或达到上面检测的抗体浓度范围内观察到的特异性溶解的最大百分数的一半所需的抗体浓度的减少。ADCC的增加是相对于采用上面测定法测定,使用本领域专业技术人员公知的相同的标准生产方法、纯化方法、配制和保存方法,由相同抗体介导的,由相同类型宿主细胞产生的,但不由被改造以过度表达GnTIII的宿主细胞产生的ADCC。
所述“增加的ADCC”可通过所述抗体的糖基化改造来获得,如Umana,P.等人,Nature Biotechnol.(自然生物技术)17(1999)176-180和US6,602,684中所述,意味着通过改造其寡糖成分来增强单克隆抗体的所述天然的、细胞介导的效应器功能。
术语“补体依赖性细胞毒性(CDC)”指由本发明所述的抗体在补体的存在下对人肿瘤靶细胞的溶解。CDC优选地通过用本发明所述的抗CD20抗体在补体的存在下处理表达CD20细胞的制剂来测定。如果4小时后抗体在100nM的浓度下诱发20%或更多的肿瘤细胞的溶解(细胞死亡),则存在CDC。该测定优选地用51Cr或Eu标记的肿瘤细胞并测定释放的51Cr或Eu来进行。对照包括肿瘤靶细胞与补体但不与抗体的孵育。
通常IgG1同种型的II型抗CD20抗体显示特征性的CDC特性。II型抗CD20抗体与IgG1同种型的I型抗体相比具有降低的CDC(如果为IgG1同种型)。优选地II型抗CD20抗体为IgG1同种型抗体。
“利妥昔单抗”抗体(参考抗体;I型抗CD20抗体的例子)是基因工程化的针对人CD20抗原的嵌合含人γ1鼠恒定区结构域的单克隆抗体。此嵌合抗体含有γ1人恒定区结构域,并且在于1998年4月17日授权并转让给IDEC制药公司(IDEC PharmaceuticalsCorporation)的US 5,736,137(Andersen,K.C.等人)中被鉴定为“C2B8”的名称。利妥昔单抗被批准用于治疗患有复发的或难治性低度或滤泡性CD20阳性的B细胞非霍奇金淋巴瘤的患者。体外作用机制研究已经显示利妥昔单抗显示人补体依赖性细胞毒性(CDC)(Reff,M.E.等人,Blood(血液)83(2)(1994)435-445)。另外,其在测定抗体依赖性细胞毒性(ADCC)的测定中显示明显的活性。
术语“人源化B-Ly1抗体”指如WO 2005/044859和WO 2007/031875中公开的人源化B-Ly1抗体,该抗体从鼠单克隆抗CD20抗体B-Ly1(鼠重链的可变区(VH):SEQ ID NO:1;鼠轻链的可变区(VL):SEQ ID NO:2-见Poppema,S.和Visser,L.,Biotest Bulletin(生物实验通报)3(1987)131-139;)通过与来自IgG1的人恒定区结构域的嵌合以及下述人源化作用(见WO2005/044859和WO 2007/031875)而获得。这些“人源化B-Ly1抗体”的详情公开在WO2005/044859和WO 2007/031875中。
优选地,“人源化B-Ly1抗体”具有选自SEQ ID No.3~SEQ ID No.20(WO 2005/044859和WO 2007/031875的B-HH2至B-HH9和B-HL8至B-HL17)的重链可变区(VH)。特别优选Seq.ID No.3、4、7、9、11、13和15(WO 2005/044859和WO 2007/031875的B-HH2、BHH-3、B-HH6、B-HH8、B-HL8、B-HL11和B-HL13)。优选地,“人源化B-Ly1抗体”具有SEQ ID No.20(WO2005/044859和WO 2007/031875的B-KV1)的轻链可变区(VL)。此外,人源化B-Ly1抗体优选是IgG1抗体。优选地,该人源化B-Ly1抗体根据WO 2005/044859、WO 2004/065540、WO 2007/031875,Umana,P.等人,Nature Biotechnol.(自然生物技术)17(1999)176-180和WO99/154342中所述的方法在Fc区被糖基化改造(GE)。该糖基化改造的人源化B-Ly1抗体在Fc区具有改变的糖基化模式,优选具有降低水平的岩藻糖残基。优选地Fc区的寡糖的至少40%或更多(在一个实施方案中为40%~60%,在另一个实施方案中为至少50%,并且还在另一个实施方案中为至少70%或更多)为非岩藻糖化的。此外,Fc区的寡糖优选地是对切的(bisected)。
寡糖成分可显著地影响与治疗性糖蛋白的功效相关的特性,包括物理稳定性,对蛋白酶攻击的抗性,与免疫系统的相互作用,药物代谢动力学,和特异的生物活性。这些特性可不仅取决于寡糖的存在与否,还取决于寡糖的特定结构。可对寡糖结构和糖蛋白功能之间做一些概括。例如,某些寡糖结构通过与特定的糖结合蛋白的相互作用而介导糖蛋白从血流中的快速清除,而其他一些寡糖则可被抗体结合并触发不需要的免疫反应。(Jenkins,N.等人,Nature Biotechnol.(自然生物技术)14(1996)975-81)。
哺乳动物细胞是生产治疗性糖蛋白的优选宿主,因为其具有以对人类应用最相容形式的糖基化蛋白的能力。(Cumming,D.A.等人,Glycobiology(糖生物学)1(1991)115-30;Jenkins,N.等人,NatureBiotechnol.(自然生物技术)14(1996)975-81)。细菌对蛋白的糖基化很罕见,并且类似于其他类型的常用宿主,诸如酵母、丝状真菌、昆虫和植物细胞,其产生与从血流中快速清除、不需要的免疫相互作用相关的糖基化模式,并且在一些特定情况下,降低生物活性。在哺乳动物细胞中,在近二十年中最常使用中国仓鼠卵巢(CHO)细胞。除了产生适当的糖基化模式以外,这些细胞能够不断地产生遗传稳定的、高产的克隆细胞系。它们可在简单的生物反应器中使用无血清培养基培养至高密度,并且允许安全可靠的发育和可重现的生物过程。其他常用的动物细胞包括幼仓鼠肾(BHK)细胞、NSO-和SP2/0-小鼠骨髓瘤细胞。近年来,还试验了由转基因动物的生产。(Jenkins,N.等人,Nature Biotechnol.(自然生物技术)14(1996)975-981)。
所有抗体在重链恒定区中的保守部位处都含有糖结构,各个同种型拥有不同的N-连接糖结构阵列,其可变地影响蛋白组装、分泌或功能性活动。(Wright,A.和Monison,S.L.,Trends Biotech.(生物技术趋势)15(1997)26-32)。附着的N-连接糖的结构变化相当大,取决于加工程度,并且可包括高甘露糖、多分支以及双分支的复合寡糖。(Wright,A.和Morrison,S.L.,Trends Biotech.(生物技术趋势)15(1997)26-32)。通常,存在附着在特定糖基化位点处的核心寡糖结构的不均一加工,使得单克隆抗体甚至以多种糖型存在。同样,已经显示细胞系之间存在抗体糖基化主要差别,并且甚至在不同培养条件下生长的指定细胞系也能见到较小的差异。(Lifely,M.R.等人,Glycobiology(糖生物学)5(8)(1995)813-22)。
获得大幅度增加的效力,同时保持简单的生产工艺并潜在地避免明显的不良副作用的一种方式是如Umana,P.等人,Nature Biotechnol.(自然生物技术)17(1999)176-180和US 6,602,684中所述,通过改造其寡糖成分来增强单克隆抗体的天然、细胞介导的效应器功能。IgG1型抗体,是在癌症免疫治疗中最常使用的抗体,其是在各个CH2结构域中Asn297处具有保守N-连接糖基化位点的糖蛋白。附着在Asn297的两个复合双分支寡糖埋藏在CH2结构域之间,形成与多肽主链的广泛接触,并且其存在对于抗体介导效应器功能诸如抗体依赖性细胞毒性(ADCC)是很重要的(Lifely,M.R.等人,Glycobiology(糖生物学)5(1995)813-822;Jefferis,R.等人,Immunol.Rev.(免疫学综述)163(1998)59-76;Wright,A.和Morrison,S.L.,Trends Biotechnol.(生物技术趋势)15(1997)26-32)。
以前显示β(1,4)-N-乙酰葡糖胺转移酶I11(“GnTII17y”)(其是一种催化对切(bisected)寡糖形成的糖基转移酶)在中国仓鼠卵巢(CHO)细胞中的过度表达显著地增加了由工程化CHO细胞产生的抗成神经细胞瘤嵌合单克隆抗体(chCE7)的体外ADCC活性。(见Umana,P.等人,NatureBiotechnol.(自然生物技术)17(1999)176-180;和WO 99/154342,其全部内容以引用方式合并于此)。抗体chCE7属于一大类未缀合的单克隆抗体,该类抗体具有很高的肿瘤亲和力和特异性,但当在缺少GnTIII酶的标准工业化细胞系中生产时效力太低而不能用于临床(Umana,P.等人,NatureBiotechnol.(自然生物技术)17(1999)176-180)。该研究首次显示通过改造抗体生产细胞以表达GnTIII将获得ADCC活性的大幅增加,还导致恒定区(Fc)相关的对切寡糖,包括对切的非岩藻糖化寡糖的比例高于天然抗体中存在的水平的增加。
术语“蛋白酶体”指26S蛋白酶体,如例如,Coux,O.,Tanaka,K.和Goldberg,A.,Ann.Rev.Biochem.(生物化学年鉴)65(1996)801-847;Voges,D.,Annu Rev Biochem.(生物化学年鉴)68(1999)1015-68或Kisselev,A.L.等人,Chem Biol(化学与生物学)Vol.8(8)(2001)739-758中所述。
如在此所使用的术语“蛋白酶体抑制剂”指抑制26S蛋白酶体的活性的药剂。此类蛋白酶体抑制剂包括,尤其是,例如肽衍生物诸如肽醛(例如,MG132、MG115、CEP-1615、PSI或免疫蛋白酶体特异性抑制剂IPSI-001(Cbz-LnL-CHO=N-苄氧甲酰基-亮氨酰基-norleucinal,见US2006/0241056)、肽硼酸盐(例如,硼替佐米(PS-341)或DFLB)、肽环氧酮(例如,环氧酶素(epoxomicin)、dihydroeponemycin或环氧酶素衍生物carfilzomib(PR-171))或肽乙烯基砜(例如,NLVS)和非肽衍生物诸如salinosporamide A(NPI-0052)、salinosporamide A衍生物、乳胱素或乳胱素衍生物(例如,clasto-乳胱素-L-内酯(omuralide)或PS-519)。所述蛋白酶体抑制剂的不同类型和结构描述在,例如,Kisselev,A.L.等人,Chem Biol(化学与生物学)Vol.8(8)(2001)739-758,WO 2004/004749和Joazeiro,C.等人,Cancer Res.(癌症研究)66(16)(2006)7840-7842),Kanagasabaphy,P.等人,Curr Opin Investig Drugs(研究药物新观点)8(2007)447-51,Adams,J.,Nat RevCancer(自然·评论·癌症)4(2004)349-360和US 2006/0241056中。
优选地,此类蛋白酶体抑制剂选自肽醛(优选N-苄氧甲酰基-亮氨酰基-norleucinal(IPSI-001))、肽硼酸盐(优选硼替佐米(PS-341))、肽环氧酮(优选环氧酶素衍生物carfilzomib(PR-171))或salinosporamide A(NPI-0052)。更优选地,此类蛋白酶体抑制剂选自硼替佐米(PS-341)、carfilzomib(PR-171)、salinosporamide A(NPI-0052)或N-苄氧甲酰基-亮氨酰基-norleucinal(IPSI-001)。
在一个优选的实施方案中,蛋白酶体抑制剂是选自肽醛(优选N-苄氧甲酰基-亮氨酰基-norleucinal(IPSI-001))、肽硼酸盐(优选硼替佐米(PS-341))或肽环氧酮的肽衍生物。在另一个优选的实施方案中,蛋白酶体抑制剂是肽硼酸盐(优选硼替佐米(PS-341);见,例如,Adams,J.,Cur.Opin.Chem Biol.(化学与生物学新观点)6(2002)493-500和US 5,780,454))。
优选地,蛋白酶体抑制剂的抗蛋白酶体抑制活性的IC50为5μM或更小,更优选1μM或更小。用于鉴定此类蛋白酶体抑制剂和用于确定抗蛋白酶体抑制活性的IC50(经连续稀释和使用非线性曲线拟合计算(XLiit软件(ID Business Solution Ltd.,Guilford,Surrey,UK))的基于细胞的测定法描述在Moravec,R.等人,Cell Notes(细胞通讯)15(2006)4-7中,该测定法使用Promega的Proteasome-GloTM基于细胞的测定试剂并采用U266细胞(人浆细胞骨髓瘤)。此“加入-混合-测量”测定法测量培养细胞中与蛋白酶体相关的糜蛋白酶样蛋白酶活性。
除了IPSI-001(Cbz-LnL-CHO=N-苄氧甲酰基-亮氨酰基-norleucinal)以外,US2006/0241056中的下列肽衍生物也是优选的蛋白酶体抑制剂:N-苄氧甲酰基-高苯丙氨酰基-phenylalanylal,N-苄氧甲酰基-亮氨酰基-phenylalanylal,N-苄氧甲酰基-丙氨酰基-phenylalanylal,N-苄氧甲酰基-甘氨酰基-脯氨酰基-丙氨酰基-phenylalanylal,N-苄氧甲酰基-甘氨酰基-脯氨酰基-苯丙氨酰基-phenylalanylal,N-苄氧甲酰基-甘氨酰基-苯丙氨酰基-phenylalanylal,N-苄氧甲酰基-亮氨酰基-正亮氨酸硼酸,N-苄氧甲酰基-苯丙氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-高苯丙氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-亮氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-甘氨酰基-脯氨酰基-丙氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-甘氨酰基-脯氨酰基-苯丙氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-亮氨酰基-亮氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-甘氨酰基-苯丙氨酰基-苯丙氨酸硼酸,N-苄氧甲酰基-亮氨酰基-正亮氨酸甲基乙烯基砜,N-苄氧甲酰基-苯丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-高苯丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-亮氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-甘氨酰基-脯氨酰基-丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-甘氨酰基-脯氨酰基-苯丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-亮氨酰基-亮氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-甘氨酰基-苯丙氨酰基-苯丙氨酸甲基乙烯基砜,N-苄氧甲酰基-亮氨酰基-正亮氨酸环氧酮,N-苄氧甲酰基-苯丙氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-高苯丙氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-亮氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-丙氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-甘氨酰基-脯氨酰基-丙氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-甘氨酰基-脯氨酰基-苯丙氨酰基-苯丙氨酸环氧酮,N-苄氧甲酰基-亮氨酰基-亮氨酰基-苯丙氨酸环氧酮,和N-苄氧甲酰基-甘氨酰基-苯丙氨酰基-苯丙氨酸环氧酮.
术语“CD20抗原的表达”意指CD20抗原在分别来自肿瘤或癌症,优选地非实体肿瘤的细胞,优选地T细胞或B细胞、更优选地B细胞的细胞表面上的显著表达水平。患有“表达CD20的癌症”的患者可通过本领域中已知的标准测定法来确定。例如,使用免疫组织化学(IHC)检测、FACS或经相应mRNA的基于PCR的检测来测定CD20抗原表达。
在此使用的术语“表达CD20的癌症”指其中癌细胞显示表达CD20抗原的所有癌症。这些表达CD20的癌症可以是,例如,淋巴瘤(lymphomas)、淋巴细胞性白血病(lymphocyticleukemias)、肺癌(lungcancer)、非小细胞肺(NSCL)癌(non small cell lung(NSCL)cancer)、支气管肺泡细胞肺癌(bronchioloalviolar cell lung cancer)、骨癌(bonecancer)、胰腺癌(pancreatic cancer)、皮肤癌(skin cancer)、头或颈癌(cancer of thehead orneck)、皮肤或眼内黑色素瘤(cutaneous or intraocular melanoma)、子宫癌(uterine cancer)、卵巢癌(ovarian cancer)、直肠癌(rectal cancer)、肛区癌症(cancerof the anal region)、胃癌(stomach cancer)、胃癌(gastric cancer)、结肠癌(coloncancer)、乳腺癌(breast cancer)、子宫癌(uterine cancer)、输卵管癌(carcinoma ofthe fallopian tubes)、子宫内膜癌(carcinoma of theendometrium)、宫颈癌(carcinomaof the cervix)、阴道癌(carcinoma of thevagina)、外阴癌(carcinoma ofthe vulva)、霍奇金病(Hodgkin′s Disease)、食管癌(cancer of the esophagus)、小肠癌(cancer ofthe small intestine)、内分泌系统癌症(cancer of the endocrine system)、甲状腺癌(cancer of the thyroidgland)、甲状旁腺癌(cancer of the parathyroid gland)、肾上腺癌(cancer of theadrenal gland)、软组织肉瘤(sarcoma of soft tissue)、尿道癌(cancer of theurethra)、阴茎癌(cancer of the penis)、前列腺癌(prostate cancer)、膀胱癌(cancer ofthe bladder)、肾癌或输尿管癌(cancer of the kidney or ureter)、肾细胞癌(renal cell carcinoma)、肾盂癌(carcinoma of the renal pelvis)、间皮瘤(mesothelioma)、肝细胞癌(hepatocellular cancer)、胆囊癌(biliary cancer)、中枢神经系统肿瘤(neoplasms of the central nervous system(CNS))、脊轴肿瘤(spinal axistumors)、脑干神经胶质瘤(brain stem glioma)、多形性成胶质细胞瘤(glioblastomamultiforme)、星形细胞瘤(astrocytomas)、神经鞘瘤(schwanomas)、室管膜瘤(ependymonas)、髓母细胞瘤(medulloblastomas)、脑膜瘤(meningiomas)、鳞状细胞癌(squamous cell carcinomas)、垂体腺瘤(pituitary adenoma),包括上述癌症的任意一种的难治性类型,和上述癌症的一种或多种的组合。
优选地,在此使用的表达CD20的癌症指淋巴瘤(优选B细胞非霍奇金淋巴瘤(B-Cell Non-Hodgkin’s lymphomas)(NHL))和淋巴细胞性白血病。这些淋巴瘤和淋巴细胞性白血病包括,例如,a)滤泡性淋巴瘤(follicularlymphomas)、b)小而未裂细胞的淋巴瘤(Small Non-Cleaved CellLymphomas)/伯基特淋巴瘤(Burkitt′s lymphoma)(包括地方性伯基特淋巴瘤(endemic Burkitt′s lymphoma))、散发性伯基特淋巴瘤(sporadicBurkitt′slymphoma)和非伯基特淋巴瘤(Non-Burkitt′s lymphoma),c)边缘区淋巴瘤(marginal zone lymphomas)(包括结外边缘区B细胞淋巴瘤(extranodalmarginal zone Bcell lymphoma)(粘膜相关淋巴组织淋巴瘤(Mucosa-associated lymphatic tissuelymphomas),MALT)、结性边缘区B细胞淋巴瘤(nodal marginal zone B cell lymphoma)和脾边缘区淋巴瘤(splenicmarginal zone lymphoma),d)外套膜细胞淋巴瘤(Mantle celllymphoma)(MCL),e)大细胞淋巴瘤(Large Cell Lymphoma)(包括B细胞弥散性大细胞淋巴瘤(B-cell diffuse large cell lymphoma)(DLCL)、弥散性混合细胞淋巴瘤(DiffuseMixed Cell Lymphoma)、免疫母细胞性淋巴瘤(ImmunoblasticLymphoma)、原发性纵隔B细胞淋巴瘤(Primary Mediastinal B-CellLymphoma)、血管中心性淋巴瘤-肺B细胞淋巴瘤(AngiocentricLymphoma-Pulmonary B-Cell Lymphoma),f)毛细胞性白血病(hairycellleukemia),g)淋巴细胞性白血病(lymphocytic lymphoma)、瓦尔登斯特伦巨球蛋白血症(waldenstrom’s macroglobulinemia)、h)急性淋巴细胞性白血病(acute lymphocyticleukemia)(ALL)、慢性淋巴细胞性白血病(chroniclymphocytic leukemia)(CLL)/小淋巴细胞性淋巴瘤(small lymphocyticlymphoma)(SLL)、B细胞型幼淋巴细胞性白血病(B-cellprolymphocyticleukemia),i)浆细胞赘生物(plasma cell neoplasms)、浆细胞骨髓瘤(plasmacell myeloma)、多发性骨髓瘤(multiple myeloma)、浆细胞瘤(plasmacytoma),j)霍奇金病(Hodgkin’s disease)。
更优选地,表达CD20的癌症是B细胞非霍奇金淋巴瘤(NHL)。特别地,表达CD20的癌症是外套膜细胞淋巴瘤(MCL)、急性淋巴细胞性白血病(ALL)、慢性淋巴细胞性白血病(CLL)、B细胞弥散性大细胞淋巴瘤(DLCL)、伯基特淋巴瘤、毛细胞性白血病、滤泡性淋巴瘤、多发性骨髓瘤、边缘区淋巴瘤、移植后淋巴增生性疾病(post transplantlymphoproliferativedisorder)(PTLD)、HIV相关淋巴瘤(HIV associated lymphoma)、瓦尔登斯特伦巨球蛋白血症、或原发性中枢神经系统淋巴瘤(primary CNS lymphoma)。
术语“治疗的方法”或其等效形式,当应用于,例如,癌症时,指被设计成减少或消除患者的癌细胞的数目,或减轻癌症的症状的操作步骤或过程。癌症或另一种增生性疾病的“治疗方法”不一定是指癌细胞或其他病症实际上被消除,细胞的数目或病症实际上被减少,或癌症或其他病症的症状实际上被减轻。经常进行治疗癌症的方法,即使成功的可能性很低,但考虑到患者的医学史和估计的预期生存期,该治疗方法仍然被认为引起了总体有益的行为过程。
术语“共同施用”或“共施用”指所述II型抗CD20抗体和所述蛋白酶体抑制剂作为一个单一制剂或作为两个独立制剂的施用。共同施用可以是同时的或以任何顺序相继的,其中优选在两种(或所有)活性剂同时发挥其生物活性时持续一定的时间段。所述II型抗CD20抗体和所述蛋白酶体抑制剂同时或相继地共施用(例如,通过连续输注经静脉内(i.v.)(对于抗体输注一次,最后对蛋白酶体抑制剂输注一次;或蛋白酶体抑制剂口服给药))。当两种治疗剂相继地共施用时,用药量在同一天以两次独立的给药来施用,或一种药剂在第1天施用,第二种在第2~第7天,优选在第2~第4天共施用。因此,术语“相继地”是指在第一抗体的用药后7天内,优选在第一抗体的用药后4天内;并且术语“同时地”是指在同一时刻。就II型CD20抗体和蛋白酶体抑制剂的维持剂量而言,术语“共同施用”是指如果治疗周期对两种药物都适合,维持剂量可例如,每周同时地共施用。或例如蛋白酶体抑制剂,例如,每第1~第3天施用,II型抗CD20抗体每周施用一次。或者维持剂量是相继共施用,或在1天内或在几天内。
不言而喻,抗体以“治疗有效量”(或简单地说“有效量”)施用于患者,该治疗有效量是将引起被研究者、兽医、内科医生(medical doctor)或其它临床医生所探寻的组织、系统、动物或人的生物或医学反应的各化合物或组合的量。
所述II型抗CD20抗体和所述蛋白酶体抑制剂共同施用的量和共同施用的时间将取决于被治疗的患者的类型(人种、性别、年龄、体重等)和状况以及被治疗的疾病或病症的严重性。所述II型抗CD20抗体和所述蛋白酶体抑制剂被适当地一次或经一系列治疗共施用于患者。根据疾病的类型和严重性,约1μg/kg~50mg/kg(例如,0.1-20mg/kg)的所述II型抗CD20抗体和1μg/kg~50mg/kg(例如,0.1-20mg/kg)的所述蛋白酶体抑制剂是用于将两种药物共同施用给患者的初次候选用药量。如果施用为静脉内给药,对于所述II型抗CD20抗体或所述蛋白酶体抑制剂的初次输注时间可以比随后的输注时间长,例如,对于初次输注约90分钟,对于随后的输注约30分钟(如果良好地耐受初次输注)。
所述II型抗CD20抗体的优选用药量在约0.05mg/kg~约30mg/kg的范围内。因此,约0.5mg/kg、2.0mg/kg、4.0mg/kg、10mg/kg或30mg/kg(或其任意组合)的一次或多次剂量可共施用于患者。所述蛋白酶体抑制剂的优选用药量在0.1mg/kg~约30mg/kg,例如对于硼替佐米为0.1mg/kg~10.0mg/kg范围之内。根据患者的类型(人种、性别、年龄、体重等)和状况以及抗CD20抗体和蛋白酶体抑制剂的类型,所述抗CD20抗体的用药量和施用日程可不同于蛋白媒体抑制剂的用药量。例如,所述抗CD20抗体可例如,每1-3周施用,并且所述蛋白酶体抑制剂可每天或每2-10天施用。也可施用较高的初次负荷剂量,紧接着一次或多次较低剂量。
在一个优选的实施方案中,药物用于预防或减少患有表达CD20的癌症的患者的转移或进一步播散。通过测定生存期、无进展生存期、反应率或反应持续时间,该药物有效用于增加该患者的生存期,增加该患者无进展生存期,增加反应持续时间,引起被治疗患者统计学显著的和临床意义的改善。在优选的实施方案中,药物用于增加一组患者中的反应率。
在本发明的上下文中,在II型抗CD20抗体和蛋白酶体抑制剂联合治疗表达CD20的癌症中,可使用附加的其他细胞毒性剂、化学治疗剂或抗癌剂,或增强这些药剂的效应的化合物(例如,细胞因子)。这些分子适当地以有效地用于预期目的的量联合存在。优选地,II型抗CD20抗体和蛋白酶体抑制剂联合治疗不使用这些附加的细胞毒性剂、化学治疗剂或抗癌剂,或增强这些药剂的效应的化合物。
这些药剂包括,例如:烷化剂或具有烷化作用的药剂,诸如环磷酰胺(cyclophosphamide)(CTX;例如,cytoxan)、苯丁酸氮芥(chlorambucil)(CHL;例如,leukeran)、顺铂(cisplatin)(CisP;例如,川铂注射剂(platinol))、白消安(busulfan)(例如,马利兰(myleran)),美法仑(melphalan)、卡莫司汀(carmustine)(BCNU)、链脲霉素(streptozotocin)、曲他胺((triethylenemelamine(TEM)、丝裂霉素C(mitomycin C)等;抗代谢物,诸如甲氨蝶呤(methotrexate)(MTX)、依托泊苷(etoposide)(VP16;例如,凡必士(vepesid))、6-巯嘌呤(6-mercaptopurine)(6MP)、6-硫鸟嘌呤(6-thiocguanine)(6TG)、阿糖胞苷(cytarabine)(Ara-C)、5-氟尿嘧啶(5-fluorouracil)(5-FU)、卡培他滨(capecitabine)(例如,适罗达(Xeloda))、达卡巴嗪(dacarbazine)(DTIC)等;抗生素,诸如放线菌素D(actinomycin D)、多柔比星(doxorubicin)(DXR;例如,阿霉素(adriamycin))、柔红霉素(daunorubicin)(道诺霉素(daunomycin))、博来霉素(bleomycin)、光辉霉素(mithramycin)等;生物碱类,诸如,长春生物碱(vinca alkaloids)诸如长春新碱(vincristine)(VCR)、长春碱(vinblastine)等;和其他抗肿瘤剂,诸如紫杉醇(paclitaxel)(例如,泰素(taxol))和紫杉醇衍生物、细胞生长抑制剂、糖皮质激素类(glucocorticoids)诸如地塞米松(dexamethasone)(DEX;例如decadron)以及皮质类固醇(corticosteroids)诸如泼尼松(prednisone)、核苷酶抑制剂诸如羟基脲(hydroxyurea)、氨基酸消耗酶类(amino aciddepleting enzyme)诸如天冬酰胺酶(asparaginase)、亚叶酸(leucovorin)和其他叶酸衍生物和类似的多种抗肿瘤剂。下列的药剂也可用作附加药剂:arnifostine (例如,ethyol)、放线菌素D(dactinomycin)、氮芥(mechlorethamine)(氮芥(nitrogen mustard))、链佐星(streptozocin)、环磷酰胺(cyclophosphamide)、洛莫司汀(lomustine)(CCNU)、多柔比星脂质体(doxorubicin lipo)(例如,doxil)、吉西他滨(gemcitabine)(例如,健择(gemzar))、柔红霉素脂质体(daunorubicin lipo)(例如,枸橼算柔红霉素脂质体(daunoxome))、丙卡巴肼(procarbazine)、丝裂霉素(mitomycin)、多西紫杉醇(docetaxel)(例如,泰索帝(taxotere))、阿地白介素(aldesleukin)、卡铂(carboplatin)、奥沙利铂(oxaliplatin)、克拉屈滨(cladribine)、喜树碱(camptothecin)、CPT 11(伊立替康)(irinotecan)、10-羟基-7-乙基-喜树碱(10-hydroxy 7-ethyl-camptothecin)(SN38)、氟尿苷(floxuridine)、氟达拉滨(fludarabine)、异环磷酰胺(ifosfamide)、伊达比星(idarubicin)、美司钠(mesna)、β干扰素(interferon beta)、α干扰素(interferonalpha)、米托蒽醌(mitoxantrone)、托泊替康(topotecan)、亮丙立德(leuprolide)、甲地孕酮(megestrol)、美法仑(melphalan)、巯嘌呤(mercaptopurine)、普卡霉素(plicamycin)、米托坦(mitotane)、培门冬酶(pegaspargase)、喷司他丁(pentostatin)、哌泊溴烷(pipobroman)、普卡霉素(plicamycin)、他莫昔芬(tamoxifen)、替尼泊苷(teniposide)、睾内酯(testolactone)、硫鸟嘌呤(thioguanine)、塞替哌(thiotepa)、乌拉莫司汀(uracilmustard)、长春瑞滨(vinorelbine)、苯丁酸氮芥(chlorambucil)。优选地II型抗CD20抗体和蛋白酶体抑制剂的联合治疗不使用这些附加药剂。
在化疗方案中上述的细胞毒性剂和抗癌剂以及抗增生靶特异性抗癌药物样蛋白激酶抑制剂的应用在癌症治疗领域中通常是被充分表征的,并且在此其应用同样要基于监测耐受性和疗效、并且控制给药途径和用药量的考虑,做一些调整。例如,细胞毒性剂的实际用药量可根据通过组织培养方法测定的患者的培养细胞反应而发生变化。一般来说,与缺少附加的其他药剂时的用量相比,用药量会减少。
有效的细胞毒性剂的典型用药量可以为供应商所推荐的范围,并且在由体外反应或动物模型中的反应来表示时,可以减少至多约一个数量级的浓度或用量。因此,实际用药量将取决于医生的判断,患者的情况,以及基于原代培养的恶性细胞或组织培养的组织样品的体外反应性、或在适当的动物模型中观察到的反应而判断的治疗方法的有效性。
在本发明的上下文中,除了II型抗CD20抗体和蛋白酶体抑制剂联合治疗表达CD20的癌症以外可进行有效量的电离辐射和/或可使用放射性药物。辐射源可以在被治疗的患者的外部或内部。当辐射源在患者的外部时,治疗被称为外光束放射疗法(external beamradiation therapy)(EBRT)。当辐射源在患者的内部时,则治疗被称为近程放射治疗(brachytherapy)(BT)。用于本发明的情形中的放射性原子可选自包括但不限于镭、铯-137、铱-192、镅-241、金-198、钴-57、铜-67、锝-99、碘-123、碘-131和铟-111的组。有可能使用这些放射性同位素来标记抗体。优选II型抗CD20抗体和蛋白酶体抑制剂的联合治疗不使用这些电离辐射。
放射治疗是用于控制不能切除或不能手术的肿瘤和/或肿瘤转移的一种标准治疗方法。当放射治疗与化疗组合时已经看到有改善的结果。放射治疗基于下面的原理,即,递送至靶区域的高剂量辐射将导致肿瘤和正常组织两者中的繁殖细胞的死亡。放射给药方案通常规定辐射吸收剂量(Gy)、时间和分级,并且必须由肿瘤学专家来小心地确定。患者接受的辐射量将取决于多种考虑事项,但两个最重要的事项是肿瘤的位置与机体的其他重要结构或器官的关系,以及肿瘤已经扩散的程度。经受放射治疗的患者的典型疗程为在1~6周的治疗日程中,施用于患者的总剂量为10~80Gy,每天约1.8~2.0Gy级分,每周5天。在本发明的优选实施方案中,当人类患者中的肿瘤采用本发明的联合治疗和放射来治疗时有协同作用。换句话说,当与放射、任选地与附加的化疗剂或抗癌剂联合使用时,通过包括本发明的组合的药剂对肿瘤生长的抑制作用得以增强。辅助放射治疗的参数,例如,见WO 99/60023。
II型抗CD20抗体根据已知方法,通过静脉推注给药或在一段时间内连续输注,通过肌内、腹膜内、脑脊液内、皮下、关节内、滑膜内或鞘内途径而施用于患者。优选抗体的静脉内或皮下给药。
蛋白酶体抑制剂根据已知方法,例如,通过静脉推注给药或在一段时间内连续输注,通过肌内、腹膜内、脑脊液内、皮下、关节内、滑膜内、鞘内或经口途径而施用于患者。优选蛋白酶体抑制剂的静脉内、皮下或口服给药。
本发明进一步包括一种试剂盒,其包括用于联合治疗患有表达CD20的癌症的患者的II型抗CD20抗体和蛋白酶体抑制剂。在一个优选的实施方案中,该试剂盒容器可进一步包括药用载体。该试剂盒可进一步包括无菌稀释剂,其优选地保存在独立的附加容器中。该试剂盒可进一步包括包装插页,该插页包括指导使用该联合治疗作为表达CD20的癌症疾病、优选B细胞非霍奇金淋巴瘤(NHL)的治疗方法的印刷说明书。
术语“包装插页”指习惯上包括在治疗产品的市售包装中的说明书,其可包括与关于这些治疗产品的应用的适应证、用法、用药量、给药、禁忌症和/或警告有关的信息。
在优选的实施方案中,产品容器的物品可进一步包括药用载体。产品的物品可进一步包括无菌稀释剂,其优选地保存在单独的附加容器中。
在此所使用的“药用载体”意在包括与药物施用相容的任何和所有物质,包括溶剂、分散介质、包衣、抗菌剂和抗真菌剂、等渗剂和吸收延迟剂,以及与药物施用相容的其他物质和化合物。除非任何常规的介质或药剂与活性化合物不相容,则其被考虑用于本发明的组合物中。补充的活性化合物也可以合并入该组合物中。
药物组合物:
可通过将本发明所述的II型抗CD20抗体和/或蛋白酶体抑制剂与药用无机或有机载体加工而获得药物组合物。可使用,例如,乳糖、玉米淀粉或其衍生物、滑石、硬脂酸或其盐类等作为用于片剂、包衣片剂、糖衣丸(dragées)和硬明胶胶囊的此类载体。用于软明胶胶囊的适当载体为,例如,植物油、蜡、脂肪、半固体和液体多元醇类等。然而,根据活性物质的特性,在软明胶胶囊中通常不需要载体。用于生产溶液和糖浆剂的适当载体为,例如,水、多元醇类、甘油、植物油等。用于栓剂的适当载体为,例如,天然或硬化油、蜡、脂肪、半固体或液体多元醇类等。
而且,药物组合物可含有防腐剂、增溶剂、稳定剂、湿润剂、乳化剂、增甜剂、着色剂、香料、用于改变渗透压的盐类、缓冲剂、掩蔽剂或抗氧化剂。它们也可含有其他的治疗上有价值的物质。
本发明的一个实施方案是一种特别用于表达CD20的癌症的包括所述II型抗CD20抗体和所述蛋白酶体抑制剂两者的药物组合物。
所述药物组合物可进一步包括一种或多种药用载体。
本发明进一步提供一种特别用于癌症的药物组合物,其包括:(i)第一有效量的II型抗CD20抗体,和(ii)第二有效量的蛋白酶体抑制剂。该组合物任选地包括药学可接受的载体和/或赋形剂。
通过将具有所需纯度的抗体与任选的药学可接受的载体、赋形剂或稳定剂混合,以冻干制剂或水溶液的形式制备根据本发明单独使用的II型抗CD20抗体的药物组合物用于储存(Remington′s Pharmaceutical Sciences(雷明顿制药学),第16版,Osol,A.主编(1980))。可接受的载体、赋形剂或稳定剂在采用的用药量和浓度下对接受者无毒性,并且包括下列各项:缓冲剂诸如磷酸盐、柠檬酸和其他有机酸;抗氧化剂,包括抗坏血酸和甲硫氨酸;防腐剂(诸如十八烷基二甲基苄基氯化铵(octadecyldimethylbenzylammoniumchloride);氯化六甲双胺(hexamethonium chloride);苯扎氯铵(benzalkoniumchloride)、苄索氯铵(benzethonium chloride);苯酚、丁醇或苯甲醇;对羟基苯甲酸烷基酯,诸如对羟基苯甲酸甲酯或丙酯;儿茶酚(catechol);间苯二酚(resorcinol);环己醇;3-戊醇;以及间甲酚;低分子量(小于约10个残基)多肽;蛋白质,诸如血清白蛋白、明胶或免疫球蛋白;亲水聚合物诸如聚乙烯吡咯烷酮;氨基酸诸如甘氨酸、谷氨酰胺、天冬酰胺、组氨酸、精氨酸或赖氨酸;单糖类、二糖类和其他糖类包括葡萄糖、甘露糖或糊精;螯合剂诸如EDTA;糖类诸如蔗糖、甘露醇、海藻糖或山梨醇;形成盐的平衡离子诸如钠;金属络合物(例如,Zn-蛋白复合物);和/或非离子型表面活性剂诸如TWEENTM、PLURONICSTM或聚乙二醇(PEG)。
单独蛋白酶体抑制剂的药学组合物,取决于其药学特性;例如,对于小的化学化合物诸如,例如,硼替佐米,例如,一种剂型可以如下:
a)片剂制剂(湿法制粒):
制备步骤:
1.将第1、2、3和4项混合并用纯水制粒。
2.将颗粒在50℃下干燥。
3.使颗粒通过适当的研磨装置。
4.加入第5项并混合3分钟;在适当的压片机上挤压。
b)胶囊制剂:
制备步骤:
1.将第1、2和3项在适当的混合机中混合30分钟。
2.加入第4和5项并混合3分钟。
3.填充至适当的胶囊中。
在本发明的一个进一步的实施方案中,根据本发明的药物组合物优选为所述II型抗CD20抗体和所述蛋白酶体抑制剂的两个单独的制剂。
活性成分也可包埋在例如通过凝聚技术或通过界面聚合(interracialpolymerization)制备的微胶囊中,所述微胶囊例如,分别用于胶体药物递送系统(例如,脂质体、白蛋白微球、微乳液、纳米颗粒和纳米胶囊)或在大乳液(macroemulsion)中的羟甲基纤维素或明胶-微胶囊和聚(甲基丙烯酸甲酯)微胶囊。这些技术公开在Remington′s Pharmaceutical Sciences(雷明顿制药学),第16版,Osol,A.主编(1980)中。
可制备缓释制剂。缓释制剂的适当例子包括含有抗体的固体疏水聚合物的半透性基质,该基质采用成形制品的形式,例如,膜,或微胶囊。缓释基质的例子包括聚酯、水凝胶(例如,聚(甲基丙烯酸2-羟基乙酯)或聚(乙烯醇))、聚丙交酯(US 3,773,919)、L-谷氨酸和L-谷氨酸γ-乙酯的共聚物、非可降解乙烯-乙酸乙酯、可降解的乳酸-乙醇酸共聚物诸如LUPRONDEPOTTM(由乳酸-乙醇酸共聚物和乙酸亮丙立德(leuprolide acetate)组成的可注射微球)、和聚-D-(-)-3-羟丁酸。
要用于体内施用的制剂必需是无菌的。这很容易地通过无菌过滤膜经过滤来完成。
本发明进一步提供了一种治疗癌症的方法,包括对需要此治疗的患者施用(i)第一有效量的II型抗CD20抗体;以及(ii)第二有效量的蛋白酶体抑制剂。
本发明进一步提供了一种治疗癌症的方法,包括对需要此治疗的患者施用(i)第一有效量的II型抗CD20抗体;以及(ii)第二有效量的蛋白酶体抑制剂。
在此施用的术语“患者”优选地指需要出于任何目的用II型抗CD20抗体治疗的人(例如,患有表达CD20的癌症的患者),并更优选地指需要该治疗来治疗癌症、或癌前病症或病变的人。然而,术语“患者”还可指非人动物,其中优选地是诸如犬、猫、马、牛、猪、羊和非人灵长类的哺乳动物。
本发明进一步包括用于与蛋白酶体抑制剂联合治疗患有表达CD20的癌症的患者的II型抗CD20抗体。
本发明进一步包括用于治疗表达CD20的癌症的II型抗CD20抗体和蛋白酶体抑制剂。
本发明进一步包括用于治疗患有表达CD20的癌症的患者的II型抗CD20抗体和蛋白酶体抑制剂。
优选地蛋白酶体抑制剂的抗蛋白酶体抑制活性的IC50为5μM或更小。优选地此类蛋白酶体抑制剂选自肽醛(优选N-苄氧甲酰基-亮氨酰基-norleucinal(IPSI-001))、肽硼酸盐(优选硼替佐米(PS-341))、肽环氧酮(优选环氧酶素衍生物carfilzomib(PR-171))或salinosporamide A(NPI-0052)。更优选地,此类蛋白酶体抑制剂选自硼替佐米(PS-341)、carfilzomib(PR-171)、salinosporamide A(NPI-0052)或N-苄氧甲酰基-亮氨酰基-norleucinal(IPSI-001)。
优选地,所述II型抗CD20抗体具有的所述II型CD20抗体与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值为0.3~0.6,更优选为0.35~0.55,并且还更优选为0.4~0.5。
优选地,所述II型抗CD20抗体是人源化B-Ly1抗体。
优选地,所述II型抗CD20抗体具有增加的抗体依赖性细胞毒性(ADCC)。
优选地,表达CD20的癌症是B细胞非霍奇金淋巴瘤(NHL)。
优选地,所述II型抗CD20抗体是单克隆抗体。
下列的实施例、序列表和附图提供用于辅助理解本发明,本发明的真正范围在附加的权利要求中给出。要理解的是在不背离本发明的精神的前提下可对给出的程序进行修改。
序列表
SEQ ID NO:1 鼠单克隆抗CD20抗体B-Ly1的重链可变区(VH)的氨基酸序列。
SEQ ID NO:2 鼠单克隆抗CD20抗体B-Ly1的轻链可变区(VL)的氨基酸序列。
SEQ ID NO:3-19 人源化B-Ly1抗体(B-HH2至B-HH9、B-HL8以及B-HL10至B-HL17)的重链可变区(VH)的氨基酸序列。
SEQ ID NO:20 人源化B-Ly1抗体B-KV1的轻链可变区(VL)的氨基酸序列。
附图说明
图1.II型抗CD20抗体(B-HH6-B-KV1GE)与蛋白酶体抑制剂(硼替佐米)的联合治疗对SU-DHL-4DLBCL B细胞非霍奇金淋巴瘤(NHL)的抗肿瘤活性,所述II型抗CD20抗体的对Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值为0.44。肿瘤体积的平均值[mm3]+/-IQR在y-轴上作图;注射肿瘤细胞后的天数在x-轴上作图。图例:A)赋形剂(圆圈),B)人源化B-ly1(B-HH6-B-KV1GE)10mg/kg每周一次(正方形),C)蛋白酶体抑制剂硼替佐米1mg/kg一周一次(三角形)以及D)人源化B-ly1(B-HH6-B-KV1GE)10mg/kg每周一次与蛋白酶体抑制剂硼替佐米(1mg/kg一周一次)共同施用(十字)。
图2.I型抗CD20抗体(Cy5-利妥昔单抗=白色条形)和II型抗CD20抗体(Cy5人源化B-Ly1 B-HH6-B-KV1 GE=黑色条形)在Raji细胞(ATCC编号:CCL-86)上的平均荧光强度(MFI,左侧y-轴);I型抗CD20抗体(利妥昔单抗)和II型抗CD20抗体(B-HH6-B-KV1 GE)与CD20的结合力与利妥昔单抗比较的比值(按比例绘制在右侧y-轴上)。
图3.两个II型抗CD20抗体的治疗对Z138人非霍奇金淋巴瘤(NHL)的抗肿瘤活性。两个抗体均为人源化B-Ly1抗CD20抗体;1)B-HH6-B-KV1糖基化改造(GE)以及2)B-HH6-B-KV1野生型(wt,未糖基化改造)。肿瘤体积的平均值[mm3]在y-轴上作图;注射肿瘤细胞后的天数在x-轴上作图。图例:A)赋形剂(圆圈),B)人源化B-Ly1 GE(B-HH6-B-KV1GE)30mg/kg每周一次(三角形),以及C)人源化B-Ly1 wt(B-HH6-B-KV1 wt)30mg/kg每周一次(十字)。
试验程序
实施例1
II型抗CD20抗体(B-HH6-B-KV1 GE)与蛋白酶体抑制剂(硼替佐米)的联合治疗的抗肿瘤活性
测试药剂
瑞士施利伦格黎卡特(GlycArt,Schlieren,Switzerland)提供的II型抗CD20抗体B-HH6-B-KV1 GE(=人源化B-Ly1,糖基化改造的B-HH6-B-KV1,见WO 2005/044859和WO2007/031875)作为母液(c=9.4mg/ml)。抗体缓冲液包括组氨酸、海藻糖和聚山梨酸酯20。注射前抗体溶液从母液中取出在PBS中适当地稀释。
蛋白酶体抑制剂硼替佐米作为临床制剂购自德国Janssen-Cilag GmbH,Neuss。从重构的储液调整稀释。
细胞系和培养条件
SU-DHL-4人非霍奇金淋巴瘤(NHL)细胞(Chang,H.等人,Leuk.Lymphoma.(白血病和淋巴瘤)8(1992)129-136)由DSMZ,Braunschweig友好提供。肿瘤细胞系常规地在添加了10%胎牛血清(PAA Laboratories,奥地利)和2mM L-谷氨酰胺的RPMI培养基(PAA,Laboratories,奥地利)中在37℃下在水饱和气氛中在5%CO2中培养。第5代用于移植。
动物
雌性SCID拜格小鼠(beige mic);到达时4-5周龄(购自Bomholtgard,Ry,丹麦)根据被批准的指导方针(GV-Solas;Felasa;TierschG)在无特异病原菌条件下饲养,每天12小时昼/12小时夜循环。试验研究方案由当地政府评审并批准。到达后,动物在动物设施的检疫区饲养一周以使其适应新环境并用于观察。定期进行连续的健康监测。随意提供进食食物(ProvimiKliba 3337)和饮水(酸化至pH 2.5-3)。
监测
每天监控动物的临床症状并检测不良反应。为了在整个试验中进行监测,动物的体重每周记录两次,并在分级后用测径器测量肿瘤体积。
动物的治疗
在细胞移植后随机的一天即22天时开始动物治疗。作为单一药剂或联合治疗的人源化II型抗CD20抗体B-HH6-B-KV1 GE接受组和相应的赋形剂组在第22、29、36和43研究日时以10mg/kg的指定用药量经静脉给药每7天1次(q7d)。蛋白酶体抑制剂硼替佐米在第23、29和37天一周一次以1mg/kg经腹膜内给药。
体内肿瘤生长抑制研究
接受赋形剂对照的具有肿瘤的动物在治疗开始后15天由于肿瘤负荷不得不被排除。与对照相比,用B-HH6-B-KV1 GE(10mg/kg)作为单剂每周一次治疗动物显著地抑制异种移植物生长14天(TGI 87%)。然而,尽管每周抗体治疗,SU-DHL-4异种移植物持续进展。相反,给予蛋白酶体抑制剂硼替佐米以1mg/kg一周一次单剂治疗,并且仅有轻微活性,与对照类似,导致肿瘤进行性地生长。尽管两种化合物作为单剂具有低活性,但在联合治疗组中,SU-DHL-4淋巴瘤异种移植物被迫使缓解。每周用B-HH6-B-KV1 GE(10mg/kg)治疗并一周一次注射蛋白酶体抑制剂硼替佐米使淋巴瘤在第一周内消失,并且在随后的联合治疗期中,9个SU-DHL-4肿瘤中的4个显示肿瘤完全消失,没有观察到再生长。
实施例2
II型抗CD20抗体的与Raji细胞(ATCC编号:CCL-86)上CD20的结合力与利妥昔单抗相比较的比值的测定
Raji细胞(ATCC-编号:CCL-86)在含有10%FCS(Gibco,Cat.-No.10500-064)的RPMI-1640培养基(PanBiotech GmbH,Cat.-No.PO4-18500)中维持培养。II型抗CD20抗体B-HH6-B-KV1(人源化B-Ly1抗体)和利妥昔单抗使用Cy5单NHS酯(Amersham GE Healthcare(安玛西亚GE卫生保健),目录号PA15101)根据供应商的说明书进行标记。Cy5-缀合的利妥昔单抗的标记比为2.0分子Cy5/抗体。Cy5-缀合的B-HH6-B-KV1的标记比为2.2分子Cy5/抗体。为了测定和比较两个抗体的结合力和模式,使用伯基特淋巴瘤细胞系Raji(ATCC-编号:CCL-86)通过直接免疫荧光生成结合曲线(通过滴定Cy5-缀合的利妥昔单抗和Cy5-缀合的B-HH6-B-KV1)。分别将Cy5-缀合的利妥昔单抗和Cy5-缀合的B-HH6-B-KV的EC50(最大强度的50%)作为平均荧光强度(MFI)来分析。5*105细胞/样品在4℃下染色30分钟。然后,细胞在培养基中洗涤。使用碘化丙啶(PI)染色来排除死细胞。使用FACSArray(BectonDickinson)进行测量。在远红外A(Far Red A)处测量碘化丙啶(PI),并且在红外-A(Red-A)处测量Cy5。图2显示在Cy5-标记的B-HH6-B-KV1(黑色条形)和Cy5-标记的利妥昔单抗(白色条形)的EC50(最大强度的50%)处结合的平均荧光强度(MFI)。
然后根据下式计算与Raji细胞(ATCC-编号:CCL-86)上CD20的结合力的比值:
因此,作为典型的II型抗CD20抗体的B-HH6-B-KV1显示结合力与利妥昔单抗相比较是减小的。
实施例3
糖基化改造(GE)和非糖基化改造的(野生型,wt)抗CD20抗体(B-HH6-B-KV1 GE和wt)对SCID拜格小鼠中的Z138MCL异种移植物的类似抗肿瘤活性
测试药剂
瑞士施利伦格黎卡特(GlycArt,Schlieren,Switzerland)提供的II型抗CD20抗体B-HH6-B-KV1(糖基化改造(GE)和野生型(wt))作为母液(c=9.4mg/ml和12.5mg/ml)提供。抗体缓冲液包括组氨酸、海藻糖和聚山梨酸酯20。
在注射前两种溶液均从母液中取出在PBS中适当地稀释。
细胞系和培养条件
Z138人B-Cell非霍奇金淋巴瘤(NHL)细胞最初获自Glycart(格黎卡特)(外套膜细胞淋巴瘤-MCL)。肿瘤细胞系常规地在添加了10%胎牛血清(PAA Laboratories,奥地利)和2mM L-谷氨酰胺的DMEM培养基(PAA,Laboratories,奥地利)中,在37℃下在水饱和气氛中在5%CO2中培养。第2代用于移植。
动物
雌性SCID拜格小鼠;到达时4-5周龄(购自Bomholtgard,Ry,丹麦)根据被批准的指导方针(GV-Solas;Felasa;TierschG)在无特异病原菌条件下饲养,每天12小时昼/12小时夜循环。试验研究方案由当地政府评审并批准。到达后,动物在动物设施的检疫区饲养一周以使其适应新环境并用于观察。定期进行连续的健康监测。随意提供进食食物(ProvimiKliba 3337)和饮水(酸化至pH 2.5-3)。
监测
每天监控动物的临床症状并检测不良反应。为了在整个试验中进行监测,动物的体重每周记录两次,并在开始分级时用测径器测量肿瘤体积。
动物的治疗
在皮下细胞移植后随机的一天即14天时开始动物治疗。人源化抗CD20抗体(B-HH6-B-KV1 GE和wt)接受组和相应的赋形剂组在第14、20、27和34研究日时以10mg/kg的指定用药量经静脉治疗每7天1次(q7d)。
体内肿瘤生长抑制研究
接受赋形剂对照的具有肿瘤的动物在治疗开始后19天由于肿瘤负荷不得不被排除。用作为wt或糖基化改造的B-HH6-B-KV1(B-HH6-B-KV1GE和wt)以10mg/kg每周一次治疗动物在开始治疗后很快抑制异种移植物的向外生长。在对照终止时,所有抗体均使肿瘤消退,并且后来大多数Z138肿瘤异种移植物显示完全消退。在此异种移植物模型中,在抗CD20抗体B-HH6-B-KV1的wt和糖基化改造形式之间没有观察到显著差异。这并非是不可能的,因为小鼠在其NK细胞上不表达正确的Fc受体,此外,由于严重的三倍体免疫缺陷,SCID拜格小鼠被认为没有发生NK-介导的ADCC的能力。因此,SCID拜格小鼠的皮下异种移植物模型不适合用于用糖基化修饰抗体模拟人ADCC介导的效应。
<110>霍夫曼-拉罗奇有限公司
<120>II型抗-CD20抗体与蛋白酶体抑制剂的联合疗法
<130>24570
<150>EP 07020820
<151>2007-10-24
<160>20
<170>PatentIn version 3.2
<210>1
<211>112
<212>PRT
<213>鼠(Mus sp.)
<220>
<221>MISC_FEATURE
<223>鼠单克隆抗-CD20抗体B-Ly1的重链可变区(VH)的氨基酸序列
<400>1
Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys
1 5 10 15
Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Met Asn Trp Val Lys Leu
20 25 30
Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Ile Phe Pro Gly Asp
35 40 45
Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr
50 55 60
Ala Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Thr Ser Leu Thr
65 70 75 80
Ser Val Asp Ser Ala Val Tyr Leu Cys Ala Arg Asn Val Phe Asp Gly
85 90 95
Tyr Trp Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
100 105 110
<210>2
<211>103
<212>PRT
<213>Mus sp.
<220>
<221>MISC_FEATURE
<223>鼠单克隆抗-CD20抗体B-Ly1的轻链可变区(VL)的氨基酸序列
<400>2
Asn Pro Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser
1 5 10 15
Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu
20 25 30
Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn
35 40 45
Leu Val Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr
50 55 60
Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val
65 70 75 80
Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly
85 90 95
Thr Lys Leu Glu Ile Lys Arg
100
<210>3
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH2)的重链可变区(VH)的氨基酸序列
<400>3
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>4
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH3)的重链可变区(VH)的氨基酸序列
<400>4
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Leu Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>5
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH4)的重链可变区(VH)的氨基酸序列
<400>5
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Va lLys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>6
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HHJ5)的重链可变区(VH)的氨基酸序列
<400>6
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>7
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH6)的重链可变区(VH)的氨基酸序列
<400>7
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>8
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH7)的重链可变区(VH)的氨基酸序列
<400>8
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>9
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH8)的重链可变区(VH)的氨基酸序列
<400>9
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>10
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HH9)的重链可变区(VH)的氨基酸序列
<400>10
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Gys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>11
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL8)的重链可变区(VH)的氨基酸序列
<400>11
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>12
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL10)的重链可变区(VH)的氨基酸序列
<400>12
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>13
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL11)的重链可变区(VH)的氨基酸序列
<400>13
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>14
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL12)的重链可变区(VH)的氨基酸序列
<400>14
Glu Val Gln Leu Val Glu Ser Gly Ala Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>15
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL13)的重链可变区(VH)的氨基酸序列
<400>15
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>16
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL14)的重链可变区(VH)的氨基酸序列
<400>16
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Lys Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>17
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL15)的重链可变区(VH)的氨基酸序列
<400>17
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Ser
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>18
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL16)的重链可变区(VH)的氨基酸序列
<400>18
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>19
<211>119
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体(B-HL17)的重链可变区(VH)的氨基酸序列
<400>19
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Ser
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210>20
<211>115
<212>PRT
<213>人工的
<220>
<223>人源化B-Ly1抗体B-KV1的轻链可变区(VL)的氨基酸序列
<400>20
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Claims (4)
1.II型抗CD20抗体在制备用于与蛋白酶体抑制剂联合治疗表达CD20的癌症的药物中的应用,其中所述II型抗CD20抗体是人源化B-Ly1抗体并且所述II型抗CD20抗体Fc区的至少40%的寡糖为非岩藻糖基化的;并且其中所述人源化B-Ly1抗体的特征在于包含SEQ IDNO:7的重链可变区氨基酸序列和包含SEQ ID NO:20的轻链可变区氨基酸序列,并且其中所述蛋白酶体抑制剂是硼替佐米,并且所述表达CD20的癌症是B-细胞非霍奇金淋巴瘤。
2.根据权利要求1所述的应用,其特征在于所述II型抗CD20抗体具有提高的抗体依赖性细胞毒性(ADCC)。
3.根据权利要求1所述的应用,其特征在于一种或多种附加的其他细胞毒性剂、化学治疗剂或抗癌剂,或增强这些药剂的作用的化合物被施用。
4.一种试剂盒,包括用于联合治疗患有表达CD 20的癌症的患者的II型抗CD20抗体和蛋白酶体抑制剂,其中所述II型抗CD20抗体是人源化B-Ly1抗体并且所述II型抗CD20抗体Fc区的至少40%的寡糖为非岩藻糖基化的;并且其中所述人源化B-Ly1抗体的特征在于包含SEQ ID NO:7的重链可变区氨基酸序列和包含SEQ ID NO:20的轻链可变区氨基酸序列,并且其中所述蛋白酶体抑制剂是硼替佐米,并且所述表达CD20的癌症是B-细胞非霍奇金淋巴瘤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07020820.2 | 2007-10-24 | ||
EP07020820 | 2007-10-24 | ||
PCT/EP2008/008919 WO2009053038A2 (en) | 2007-10-24 | 2008-10-22 | Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102083499A CN102083499A (zh) | 2011-06-01 |
CN102083499B true CN102083499B (zh) | 2016-12-14 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101827611B (zh) | Ⅱ型抗CD20抗体在制备用于与抗Bcl-2活性剂联合治疗表达CD20的癌症的药物中的应用 | |
CN101821292B (zh) | Ⅰ型和ⅱ型抗-cd20抗体的组合疗法 | |
RU2520757C2 (ru) | Комбинированная терапия антителами анти-cd20 типа ii в сочетании с ингибитором протеасом | |
CN101983071A (zh) | 具有增加的抗体依赖性细胞毒性(adcc)的ⅱ型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用 | |
CN104768581A (zh) | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 | |
CN102596245A (zh) | 无岩藻糖基化cd20抗体与苯达莫司汀的联合疗法 | |
CN102470172B (zh) | 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法 | |
CN103261229A (zh) | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 | |
CN102844049A (zh) | 无岩藻糖基化CD20抗体与mTOR抑制剂的联合疗法 | |
CN103096926A (zh) | 无岩藻糖基化cd20抗体与抗vegf抗体的联合疗法 | |
CN102083499B (zh) | Ii型抗cd20抗体与蛋白酶体抑制剂的联合疗法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |